AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 280: H2413-H2416, 2001;
0363-6135/01 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (33)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campbell, W. B.
Right arrow Articles by Harder, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campbell, W. B.
Right arrow Articles by Harder, D. R.
Vol. 280, Issue 6, H2413-H2416, June 2001

SPECIAL TOPIC
Prologue: EDHF-what is it?

William B. Campbell and David R. Harder

Departments of Pharmacology and Toxicology and Physiology, Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226


    ARTICLE
TOP
ARTICLE
REFERENCES

ENDOTHELIAL CELLS regulate vascular tone through the release of soluble mediators such as prostacyclin, nitric oxide (NO), and endothelium-derived hyperpolarizing factor (EDHF). This issue of AJP: Heart & Circ Physiol contains nine research articles covering the topic of EDHF. These articles consider the identity of EDHF, the mechanism of action of EDHF, the role of gap junctions in the EDHF response, and the influence of shear stress and gender on EDHF. The articles include studies in isolated vessels of humans and experimental animals as well as a clinical study in humans. These articles do not represent all aspects or all points of view in this field of investigation, but they are a snapshot of important original contributions to our understanding of the physiology of EDHF. As expected, the contributors do not reach a consensus on the nature of EDHF. However, many of the salient arguments are discussed and several consistent properties of EDHF are defined.

As originally described, acetylcholine caused hyperpolarization of vascular smooth muscle in arteries with an intact endothelium but not in the absence of the endothelium (6, 10, 11, 21). The hyperpolarization by acetylcholine was inhibited by high extracellular potassium concentration and potassium channel blockers and mimicked by potassium channel agonists. The activity was not affected by inhibitors of NO synthase or cyclooxygenase. This pioneering research established the existence of EDHF and indicated that it was distinct from NO or prostacyclin. Furthermore, these studies implied that EDHF acted to open smooth muscle cell potassium channels, allowing potassium efflux along its chemical gradient and resulting in membrane hyperpolarization. These conclusions have been confirmed by subsequent investigations including some of the articles in this Special Topic. Because few laboratories are equipped to measure membrane potential in smooth muscle cells, another functional definition of EDHF has subsequently emerged: agonist-induced, endothelium-dependent relaxations that are not blocked by inhibitors of NO synthase or cyclooxygenase but are inhibited by potassium channel blockers. These two definitions are assumed to define the same mediator.

The relative contributions of NO, prostacyclin, and EDHF in regulating vascular tone have not been clearly defined. However, in vitro studies with inhibitors of the synthesis of these mediators indicate that the contribution of NO to vascular tone is greatest in large-diameter vessels, whereas the contribution of EDHF is greatest in small-diameter vessels and microvessels (36). This conclusion has been confirmed in vivo (37, 43). In this regard, the studies by Coleman et al. (12), Wu et al. (44), Huang et al. (32), and Zhang et al. (45) in this Special Topic were all conducted in arterioles and indicate the role of EDHF to arteriolar tone.

The chemical identity of EDHF is controversial. Several chemical mediators produced by the endothelium have EDHF activity in some vascular beds. Studies from a number of laboratories (7, 22, 24, 25, 31, 39) indicate that epoxyeicosatrienoic acids (EETs) function as EDHF. EETs are cytochrome P-450 metabolites of arachidonic acid and are produced by the endothelium (39, 40). They are released in response to acetylcholine, hyperpolarize smooth muscle, open calcium-activated potassium channels, and relax arteries. Inhibitors of cytochrome P-450 inhibit acetylcholine-induced hyperpolarization of smooth muscle and relaxation. Indeed, the EETs are the only endothelial factors that hyperpolarize vascular smooth muscle that has been identified by chemical methods (7, 40). In other studies, inhibitors of cytochrome P-450 failed to affect the EDHF response (13, 20, 41). In an accompanying article, Halcox et al. (27) confirm the role of cytochrome P-450 metabolites in regulating vascular tone in human subjects. They report that acetylcholine and bradykinin dilate the human forearm vasculature in the presence of NO synthase and cyclooxygenase blockade. Infusion of potassium chloride blocked the dilation to bradykinin. The cytochrome P-450 inhibitor miconazole also blocked the bradykinin-induced vasodilation but not the dilation to acetylcholine. The authors concluded that EDHF is an EET in the human forearm microvasculature. Similarly, Wu et al. (44) report flow-induced dilation in the presence of NO synthase and cyclooxygenase blockade that was blocked by the potassium channel blocker charybdotoxin. Two inhibitors of cytochrome P-450 also blocked the dilation. These authors concluded that EDHF, a cytochrome P-450 metabolite, preserves flow-induced dilation in female rats. Finally, Zhang and co-workers (45) compared the ability of stereoisomers and regioisomers of the EETs as well as EET analogs with a Delta 17 double bond and with two additional carbons to relax coronary microvessels and activate calcium-activated potassium channels in coronary myocytes. These analogs and isomers had similar activity. There was no apparent regioselectivity or stereoselectivity in causing relaxation. In addition, the analogs were comparable in potency and activity to the naturally occurring EETs. These articles further emphasize a role for EETs as a mediator of endothelium-dependent relaxations in the presence of cyclooxygenase and NO synthase inhibition.

All of the articles in this Special Topic, and most articles in the literature, use inhibitors of cytochrome P-450 to define the role of the EETs as EDHFs. Identification of EETs as EDHF by pharmacological approaches alone should be viewed with caution. Similarly, a lack of effect of cytochrome P-450 inhibitors does not establish that EDHF is not a cytochrome P-450 metabolite unless enzyme inhibition is chemically verified because there are many cytochrome P-450 isozymes with different affinities for substrates and inhibitors. For example, the cytochrome P-450 inhibitor 17-octadecynoic acid inhibits the omega -hydroxylation of arachidonic acid by cytochrome P-450 at low concentrations and inhibits epoxygenase activity in fivefold higher concentrations (29). In addition, in the smooth muscle cells of some vessels, arachidonic acid is metabolized by cytochrome P-450 to the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE) (30, 34). Inhibitors of cytochrome P-450 will block the formation of both endothelial vasodilator EETs and smooth muscle cell constrictor 20-HETE (8).

Of interest, these studies by Halcox et al. (27), Huang et al. (32), and Wu et al. (44) emphasize a role for EDHF following inhibition of NO synthase and in NO synthase knockout mice. Others (3) reported that NO inhibits EDHF release. Because NO binds heme, it has been suggested that NO binds and inactivates cytochrome P-450 epoxygenase and blocks EET synthesis. Alternatively, Dora and co-workers (15) suggested that NO may inhibit EDHF release by increasing cGMP and protein kinase G and inhibiting calcium entry into endothelial cells via a protein kinase G-regulated cation channel.

Potassium causes vasodilation in low concentrations by activation of the sodium-potassium ATPase (18, 19). In the rat hepatic artery, acetylcholine promotes the release of potassium from endothelial cells through potassium channel activation. Potassium causes hyperpolarization and relaxation of smooth muscle in concentrations <14 mM. However, in concentrations >14 mM, it will depolarize and contract the smooth muscle. Thus potassium functions as an EDHF within the concentration window of 4.8-14 mM. The article by Dora and Garland (14) supports this view. However, other laboratories have concluded that potassium is not EDHF (16, 17, 33, 38). This discrepancy may be attributed to the narrow concentration window in which potassium causes hyperpolarization and dilation. It has been suggested that EETs mediate the opening of potassium channels in endothelial cells, and endothelial potassium mediates the hyperpolarization and vasodilation. Another study (38) contradicts this conclusion and indicates that EETs act on the smooth muscle cells to cause dilation. Coleman et al. (12) present evidence in guinea pig submucosal arterioles that substance P promotes endothelium-dependent hyperpolarization of the smooth muscle cell membrane, whereas potassium chloride promotes depolarization. These authors conclude that EDHF is not potassium in the guinea pig arterioles. Instead, these investigators provide evidence for the electrotonic spread of current from endothelial cells to smooth muscle cells. This idea of electrical coupling of endothelial cells and smooth muscle cells through gap junction is of growing importance. There is a need for additional research on the contribution of endothelial-muscle cell gap junctions and their role in the mechanism of EDHF. Because vascular smooth muscle cells are much larger than endothelial cells, it is not obvious how hyperpolarization of an endothelial cell will promote hyperpolarization of an electrically coupled smooth muscle cell. Under normal circumstances, the potential voltage and current density of the larger cell will control the membrane potential of the smaller cell, not vice versa. Additionally, there is not a one-to-one coupling of endothelial cells to smooth muscle cells. These concerns raise the issue of whether the electrical coupling between endothelial cells or between smooth muscle cells is critical for the EDHF response or the spread of the EDHF effect. Chaytor et al. (9) investigated the contribution of electrical coupling using synthetic peptides homologous to specific regions of the connexins that comprise vascular gap junctions. These "Gap" peptides are specific for connexin40 and -43, which are present in gap junctions of endothelial cells of the rat hepatic artery, and specific for connexin37, which is present in smooth muscle cell gap junctions. Inhibition of connexins with these Gap peptides blocked gap junction formation. Furthermore, a combination of the Gap peptides that block connexin40, -43, and -37 inhibited acetylcholine-induced relaxations in rat hepatic arteries pretreated with inhibitors of NO synthase and cyclooxygenase. These studies emphasize the importance of gap junctions in the transmission and spread of the EDHF response.

Several reports suggest that hydrogen peroxide functions as EDHF (5, 35). Other reports document the ability of reactive oxygen species (ROS) to increase potassium channel activity and hyperpolarize smooth muscle (1, 2). There are several potential sources of superoxide anion in endothelial cells, including NADPH oxidase, NO synthase, and cytochrome P-450 (4, 23, 42). Superoxide dismutase converts superoxide to hydrogen peroxide. Thus ROS fit the basic profile of EDHF; however, it remains to be determined whether ROS play a physiological role in this regard. Hamilton and co-workers (28) performed studies in the radial and internal mammary arteries of humans to determine the role of hydrogen peroxide. These arteries produce superoxide and contain superoxide dismutase and have the capacity to produce hydrogen peroxide. However, neither catalase nor superoxide dismutase inhibited the relaxations to carbachol in arteries treated with inhibitors of NO synthase and cyclooxygenase. Whereas human radial and internal mammary arteries exhibit EDHF-mediated relaxations, these relaxations cannot be attributed to hydrogen peroxide.

The articles by Wu et al. (26) and Golding et al. (44) indicate that the contribution by EDHF differs in females and males, and estrogen may be responsible. These studies, however, describe opposite results. Wu and co-workers (44) demonstrate that arterioles of the gracillis muscle dilate in response to increases in flow. This dilation occurred in both males and females; however, the response was greater in females. The flow-mediated dilation was eliminated by inhibition of NO synthase and cyclooxygenase in males but not in females. Inhibitors of cytochrome P-450 and potassium channels eliminated the response in females. The authors concluded that EDHF preserved flow-mediated dilation in females but not males. Golding and co-workers (26) reported that middle cerebral arteries relaxed to ATP in the presence of inhibitors of NO synthase and cyclooxygenase. These relaxations were less in females and in estrogen-treated, ovariectomized females than in males or ovariectomized females. These studies by Wu et al. (26) and Golding et al. (44) were performed in arterioles from different vascular beds, raising the possibility that gender or estrogen may have differential effects on the circulation. Obviously, this important issue requires further study and clarification.

These articles represent the growing interest in EDHF and its role in the control of regional circulations under normal conditions and in disease. These studies also indicate the challenge for future research to define the roles of EETs, hydrogen peroxide, and potassium; determine the interactions among NO, prostacyclin, and EDHF; and clarify the participation of gap junctions in mediating and spreading the EDHF response in the vascular wall.


    FOOTNOTES

 This special topic section is a collection of papers accepted under a special call for manuscripts by the Editor. See Journal web site for information about the next call.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
TOP
ARTICLE
REFERENCES

1.   Barlow, RS, El-Mowafy AM, and White RE. H2O2 opens BKCa channels via the PLA2-arachidonic acid signaling cascade in coronary artery smooth muscle. Am J Physiol Heart Circ Physiol 279: H475-H483, 2000[Abstract/Free Full Text].

2.   Barlow, RS, and White RE. Hydrogen peroxide relaxes porcine coronary arteries by stimulating BKCa channel activity. Am J Physiol Heart Circ Physiol 255: H1283-H1289, 1988.

3.   Bauersachs, J, Popp R, Hecker M, Sauer E, Fleming I, and Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94: 3341-3347, 1996[Abstract/Free Full Text].

4.   Bayraktutan, U, Blayney L, and Shah AM. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler Thromb Vasc Biol 20: 1903-1911, 2000[Abstract/Free Full Text].

5.   Beny, JL, and von der Weid PY. Hydrogen peroxide: an endogenous smooth muscle cell hyperpolarizing factor. Biochem Biophys Res Commun 176: 378-384, 1991[Web of Science][Medline].

6.   Bolton, TB, and Clapp LH. Endothelial-dependent relaxant actions of carbachol and substance P in arterial smooth muscle. Br J Pharmacol 87: 713-723, 1986[Web of Science][Medline].

7.   Campbell, WB, Gebremedhin D, Pratt PF, and Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423, 1996[Abstract/Free Full Text].

8.   Campbell, WB, and Harder DR. Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84: 484-488, 1999[Free Full Text].

9.   Chaytor, AT, Martin PEM, Edwards DH, and Griffith TM. Gap junctional communication underpins EDHF-type relaxations evoked by acetylcholine in the rat hepatic artery. Am J Physiol Heart Circ Physiol 280: H2441-H2450, 2001[Abstract/Free Full Text].

10.   Chen, G, Suzuki H, and Weston AH. Acetylcholine released endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 95: 1165-1174, 1988[Web of Science][Medline].

11.   Cohen, RA, and Vanhoutte PM. Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic GMP. Circulation 92: 3337-3349, 1995[Free Full Text].

12.   Coleman, HA, Tare M, and Parkington HC. EDHF is not K+ but may be due to spread of current from the endothelium in guinea pig arterioles. Am J Physiol Heart Circ Physiol 280: H2478-H2483, 2001[Abstract/Free Full Text].

13.   Corriu, C, Feletou M, Canet E, and Vanhoutte PM. Inhibitors of the cytochrome P450-mono-oxygenase and endothelium-dependent hyperpolarizations in the guinea-pig isolated carotid artery. Br J Pharmacol 117: 607-610, 1996[Web of Science][Medline].

14.   Dora, KA, and Garland CJ. Properties of smooth muscle hyperpolarization and relaxation to potassium in the rat isolated mesenteric artery. Am J Physiol Heart Circ Physiol 280: H2424-H2429, 2001[Abstract/Free Full Text].

15.   Dora, KA, Garland CJ, Kwan HY, and Yao X. Endothelial cell protein kinase G inhibits release of EDHF through a PKG-sensitive cation channel. Am J Physiol Heart Circ Physiol 280: H1272-H1277, 2001[Abstract/Free Full Text].

16.   Doughty, JM, Boyle JP, and Langton PD. Potassium does not mimic EDHF in rat mesenteric arteries. Br J Pharmacol 130: 1174-1182, 2000[Web of Science][Medline].

17.   Drummond, GR, Selemidis S, and Cocks TM. Apamin-sensitive, non-nitric oxide (NO) endothelium-dependent relaxations to bradykinin in the bovine isolated coronary artery: no role for cytochrome P450 or K+. Br J Pharmacol 129: 811-819, 2000[Web of Science][Medline].

18.   Edwards, G, Dora KA, Gardener MJ, Garland CJ, and Weston AH. K is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 396: 269-272, 1998[Medline].

19.   Edwards, G, Gardener MJ, Feletou M, Brady G, Vanhoutte PM, and Weston AH. Further investigation of endothelium-derived hyperpolarizing factor (EDHF) in rat hepatic artery: studies using 1-EBIO and ouabain. Br J Pharmacol 128: 1064-1070, 1999[Web of Science][Medline].

20.   Edwards, G, Zygmunt PM, Hogestatt ED, and Weston AH. Effects of cytochrome P450 inhibitors on potassium currents and mechanical activity in rat portal vein. Br J Pharmacol 119: 691-701, 1996[Web of Science][Medline].

21.   Feletou, M, and Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 93: 515-524, 1988[Web of Science][Medline].

22.   Fisslthaler, B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497, 1999[Medline].

23.   Fleming, I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, and Busse R. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88: 44-51, 2001[Abstract/Free Full Text].

24.   Fulton, D, McGiff JC, and Quilley J. Pharmacological evaluation of an epoxide as the putative hyperpolarizing factor mediating the nitric oxide-independent vasodilator effect of bradykinin in the rat heart. J Pharmacol Exp Ther 287: 497-503, 1998[Abstract/Free Full Text].

25.   Gebremedhin, D, Harder DR, Pratt PF, and Campbell WB. Bioassay of an endothelium-derived hyperpolarizing factor from bovine coronary arteries: role of a cytochrome P450 metabolite. J Vasc Res 35: 274-284, 1998[Web of Science][Medline].

26.   Golding, EM, and Kepler TE. The role of estrogen in modulating EDHF-mediated dilations in the female rat middle cerebral artery. Am J Physiol Heart Circ Physiol 280: H2417-H2423, 2001[Abstract/Free Full Text].

27.   Halcox, JPJ, Narayanan S, Crames-Joyce L, Mincemoyer R, and Quyyumi AA. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am J Physiol Heart Circ Physiol 280: H2470-H2477, 2001[Abstract/Free Full Text].

28.   Hamilton, CA, McPhaden AR, Berg G, and Dominiczak AF. Is hydrogen peroxide an EDHF in human radial arteries? Am J Physiol Heart Circ Physiol 280: H2451-H2455, 2001[Abstract/Free Full Text].

29.   Harder, D, Campbell WB, and Roman RJ. Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone. J Vasc Res 32: 79-92, 1995[Web of Science][Medline].

30.   Harder, DR, Gebremedhin D, Narayanan J, Jefcoat C, Falck JR, Campbell WB, and Roman R. Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol Heart Circ Physiol 266: H2098-H2107, 1994[Abstract/Free Full Text].

31.   Hecker, M, Bara AT, Bauersachs J, and Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol (Lond) 481: 407-414, 1994[Abstract/Free Full Text].

32.   Huang, A, Sun D, Carroll MA, Jiang H, Smith CJ, Connetta JA, Shesely EG, Koller A, and Kaley G. EDHF is released to flow in skeletal muscle arterioles of female eNOS-KO mice. Am J Physiol Heart Circ Physiol 280: H2462-H2469, 2001[Abstract/Free Full Text].

33.   Lacy, PS, Pilkington G, Hanvesakul R, Fish HJ, Boyle JP, and Thurston H. Evidence against potassium as an endothelium-derived hyperpolarizing factor in rat mesenteric small arteries. Br J Pharmacol 129: 605-611, 2000[Web of Science][Medline].

34.   Ma, YH, Gebremedhin D, Schwartzman ML, Falck JR, Clark JE, Masters BS, Harder DR, and Roman RJ. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries. Circ Res 72: 126-136, 1993[Abstract/Free Full Text].

35.   Matoba, T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kandaide H, and Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 106: 1521-1530, 2000[Web of Science][Medline].

36.   Nagao, T, Illiano S, and Vanhoutte PM. Heterogenous distribution of endothelium-dependent relaxations resistant to N-nitro-L-arginine in rats. Am J Physiol Heart Circ Physiol 263: H1090-H1094, 1992[Abstract/Free Full Text].

37.   Nishikawa, Y, Stepp DW, and Chilian WM. In vivo location and mechanism of EDHF-mediated vasodilation in canine coronary microcirculation. Am J Physiol Heart Circ Physiol 277: H1252-H1259, 1999[Abstract/Free Full Text].

38.   Pratt, PF, Li P, Hillard CJ, Kurian J, and Campbell WB. Endothelium-independent, ouabain-sensitive relaxation of bovine coronary arteries by EETs. Am J Physiol Heart Circ Physiol 280: H1113-H1121, 2001[Abstract/Free Full Text].

39.   Rosolowsky, M, and Campbell WB. Role of PGI2 and EETs in the relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol Heart Circ Physiol 264: H327-H335, 1993[Abstract/Free Full Text].

40.   Rosolowsky, M, and Campbell WB. Synthesis of hydroxyeicosatetraenoic acids (HETEs) and epoxyeicosatrienoic acids (EETs) by cultured bovine coronary artery endothelial cells. Biochim Biophys Acta 1299: 267-277, 1996[Medline].

41.   Vanheel, B, and Van de Voorde J. Evidence against the involvement of cytochrome P450 metabolites in endothelium-dependent hyperpolarization of the rat main mesenteric artery. J Physiol (Lond) 501: 331-341, 1997[Abstract/Free Full Text].

42.   Vasquez-Vivar, J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, and Pritchard KA. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 95: 9220-9225, 1998[Abstract/Free Full Text].

43.   Widmann, MD, Weintraub NL, Fudge JL, Brooks LA, and Dellsperger KC. Cytochrome P-450 pathway in acetylcholine-induced canine coronary microvascular vasodilation in vivo. Am J Physiol Heart Circ Physiol 274: H283-H289, 1998[Abstract/Free Full Text].

44.   Wu, Y, Huang A, Sun D, Falck JR, Koller A, and Kaley G. Gender specific compensation for the lack of nitric oxide in the mediation of flow-indiced arteriolar dilation. Am J Physiol Heart Circ Physiol 280: H2456-H2461, 2001[Abstract/Free Full Text].

45.   Zhang, Y, Ottman CL, Lu T, Lee HC, Dellsperger KC, and VanRollins M. EET homologs potently dilate coronary microvessels and activate large conductance Ca2+-activated potassium channels. Am J Physiol Heart Circ Physiol 280: H2430-H2440, 2001[Abstract/Free Full Text].


Am J Physiol Heart Circ Physiol 280(6):H2413-H2416
0363-6135/01 $5.00 Copyright © 2001 the American Physiological Society



This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. B. Gombos, V. Wolan, K. McDonald, and D. G. Hemmings
Impaired vascular function in mice with an active cytomegalovirus infection
Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H937 - H945.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. K. Brzezinska, D. Merkus, and W. M. Chilian
Metabolic communication from cardiac myocytes to vascular endothelial cells
Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2232 - H2237.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J.-A. Haefliger, P. Nicod, and P. Meda
Contribution of connexins to the function of the vascular wall
Cardiovasc Res, May 1, 2004; 62(2): 345 - 356.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C.-L. M Cooke and S. T Davidge
Endothelial-dependent vasodilation is reduced in mesenteric arteries from superoxide dismutase knockout mice
Cardiovasc Res, December 1, 2003; 60(3): 635 - 642.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Vigili de Kreutzenberg, E. Kiwanuka, A. Tiengo, and A. Avogaro
Visceral obesity is characterized by impaired nitric oxide-independent vasodilation
Eur. Heart J., July 1, 2003; 24(13): 1210 - 1215.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Morio, E. P. Carter, M. Oka, and I. F. McMurtry
EDHF-mediated vasodilation involves different mechanisms in normotensive and hypertensive rat lungs
Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1762 - H1770.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (33)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campbell, W. B.
Right arrow Articles by Harder, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campbell, W. B.
Right arrow Articles by Harder, D. R.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online